Fig. 1. Effects of IACS-010759 on tumor growth, cell proliferation, and cell death in vivo.

(A) Individual mouse weights over time following treatment with DMSO or IACS-010759 (5 or 10 mg/kg). n = 6 mice per group. (B) SK-N-AS tumor growth curves normalized to size at start of treatment (n = 6 mice per group). (C) Fold increase in SK-N-AS tumor volume over 5 days of treatment with DMSO or IACS-010759 (DMSO, n = 16; IACS-010759, n = 18). (D and E) Percentage of Ki67- and TUNEL-positive nuclei following treatment with DMSO or IACS-010759 (n = 5 mice per group, SK-N-AS xenograft). (F to H) Fold increase in tumor volume over 5 days for BE(2)C (DMSO, n = 20; IACS-010759, n = 20), HCC827 (DMSO, n = 5; IACS-010759, n = 5), and A549 (DMSO, n = 5; IACS-010759, n = 5) xenografts, treated with either DMSO or IACS-010759. Statistical significance was assessed using log₂-transformed least squares line fitting followed by extra sum-of-square F tests for the differences between lines and Holm-Sidak’s method for multiple comparisons adjustment (B), log₂-transformed two-way one-way analyses of variance (ANOVAs) followed by Sidak’s multiple comparisons adjustment (C, F, G, and H), or Student’s t tests followed by Holm-Sidak’s multiple comparisons adjustment (D and E). Statistical tests were two-sided. Data represent means ± SD. *P = 0.01 to 0.05 and ***P = 0.0001 to 0.001. NS, not significant.